PLYMOUTH MEETING, Pa., Sept. 17, 2012 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx) announced today that Calvin Sumner M.D., chief medical officer and SVP of clinical development, will be presenting at the BioPharm America Conference taking place September 19-21, 2012 and Byron Hewett, chairman and CEO, will be presenting at the AdvaMed MedTech Conference taking place October 1-3, 2012, both in Boston, MA.
BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).
Dr. Sumner and Mr. Hewett will provide a company overview and update on the Quotient System during their presentations:
Event:BioPharm America 2012 ConferenceDate: Friday, September 21, 2012 Time: 10:25 am ETLocation:Hancock Room; Westin Boston WaterfrontEvent:AdvaMed 2012 MedTech ConferenceDate: Tuesday, October 2, 2012 Time: 11:10 am ETLocation:Room 051; Boston Convention & Exhibition Center
About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD. Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity. Patients may be re-assessed periodically at follow-up visits to guide treatment plans. The clinician integrates the Quotient® report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information please visit: '/>"/>
|SOURCE BioBehavioral Diagnostics Company|
Copyright©2012 PR Newswire.
All rights reserved